CAR-T: from bed to bench and back again

Learn about treatment development and the CAR-T manufacturing process from the presenters of the Kite Satellite Symposium ‘CAR T: from bed to bench and back again’.

Hosted during the 15th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland, these sessions included discussion on licensed products, and were organized and fully funded by Kite, a Gilead Company.

Apheresis overview

Claire Roddie, MD, PhD from University College London (UCL), UK, discusses the T-cell apheresis process, and why it is critical to deliver a high-quality final CAR-T product. She goes on to discuss some of the challenges of harvesting patient’s T-cells.

Optimizing apheresis in a routine setting

Dr Roddie speaks about the UCL approach to ensuring an optimal T-cell apheresis process in the clinical setting, and standardizing treatment across centers.

Challenges and potential solutions to scaling up

Dr Roddie gives solutions for some of the key challenges presented by the apheresis process and suggests how CAR T-cell manufacturing could be scaled up.

Evolution of CAR T-cell therapy

John Rossi, MS, Director of Translational Medicine at Kite, a Gilead Company, summarizes the history and progression of CAR T-cell therapy. He outlines advancements in recent years and future expansion plans at Kite.

The importance of robust manufacturing in CAR T-cell therapy

Chris Shen, PhD, Director of Manufacturing Science and Technology at Kite, a Gilead Company, describes the steps of the autologous CAR T-cell manufacturing process, from isolation to anti-CD3 antibody activation, transduction expansion, formulation and cryopreservation. He then discusses what the future potentially holds for CAR T-cell manufacturing in Europe.

The importance of quality control and lot release tests

Christian Chabannon, MD, PhD, of the Institut Paoli Calmettes, Marseille, France, outlines the importance of CAR T-cell therapy lot release tests and the stages of quality control during the manufacturing process.

Expanding the Kite CAR-T team in Europe

Louis van de Wiel, Vice President and Site Head at Kite, a Gilead Company, gives an overview of Kite’s expansion strategies, including the optimization of treatment in Europe through building new facilities and expanding the CAR-T team at the company.

Axicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Axicabtagene ciloleucel must be administered at a qualified clinical setting.

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead at safety_FC@gilead.com or +44 (0) 1223 897500.

YESCARTA® (axicabtagene ciloleucel), Kite and the Kite logo are registered trademarks of Kite Pharma Inc © 2019 Kite Pharma, Inc.